A nuclear deal with Iran boosted the markets to a higher close with the Dow climbing 75 points to 18,053. Nasdaq gained 33 points to 5,104.

On the upside

Zogenix (Nasdaq: ZGNX) will delay the start of Phase 3 clinical trials of its epilepsy drug ZX008 by three months in order to enroll more patients.

Bargain hunters lifted shares of SeaSpine Holdings (Nasdaq: SPNE).
 
Epirus Biopharmaceuticals (Nasdaq: EPRS) entered a multi-product, multi-region, profit-sharing collaboration with Polpharma Group.
 
On the downside

Hynes Keller & Hernandez launched an investigation into InterCloud Systems (NYSE: ICLD) for a potential breach of fiduciary responsibilities.

Shares of FormFactor (Nasdaq: FORM) fell on rumors that client Micron Technology (Nasdaq: MU) may be sold.

Primero Mining (NYSE: PPP) warned that silver sales were delayed at its Primero Empresa Minera subsidiary.

In the broad market, advancing issues outpaced decliners by a margin of more than 5  to 3 on both the NYSE and on Nasdaq. The broader S&P 500 gained 9 points to 2108. Bitcoin eased a point to $285.